Loading...
•
Dec 31, 2019
AptarGroup Q4 2019 Earnings Report
AptarGroup's Q4 2019 financial performance was reported, with sales decreasing due to currency exchange rates and core sales declining due to lower resin costs, while strategic steps were highlighted to strengthen the beauty business.
Key Takeaways
AptarGroup reported a decrease in sales for Q4 2019, with reported sales at $671 million, a 2% decrease compared to the previous year, impacted by currency exchange rates and lower resin costs. The Pharma segment experienced core sales growth, which was offset by decreases in other segments. Reported earnings per share were $0.73, while adjusted earnings per share were $0.80.
Reported sales decreased by 2% due to currency exchange rates.
Core sales declined by 1% due to lower resin costs.
Pharma segment's core sales growth was offset by decreases in other segments.
Adjusted earnings per share decreased to $0.80 from $0.92 in the prior year.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Revenue by Segment
Aptar Pharma Revenue
CapyFin.comAptar Beauty Revenue
CapyFin.comAptar Closures Revenue
CapyFin.com Forward Guidance
Aptar expects earnings per share for the first quarter of 2020, excluding any restructuring costs and acquisition-related expenses, to be in the range of $0.85 to $0.93 and this guidance is based on an effective tax rate range of 28% to 30%.
Positive Outlook
- Optimistic about the long-term opportunities for growth
- Excited about recent strategic acquisitions and investments.
Challenges Ahead
- Beauty + Home customers continuing to focus on inventory reductions
- Current macroeconomic uncertainties including the negative impact of the coronavirus outbreak
- Travel retail industry is particularly exposed
- Pharma segment is facing difficult comparisons compared to the prior year’s exceptional growth
- Food + Beverage segment’s Asian business may also be negatively affected by the coronavirus impact.
Revenue & Expenses
Visualization of income flow from segment revenue to net income